<DOC>
	<DOCNO>NCT02135822</DOCNO>
	<brief_summary>The purpose study determine efficacy safety nanoparticle albumin-bound paclitaxel ( nab-paclitaxel ) plus gemcitabine first-line treatment Chinese patient advance pancreatic ductal adenocarcinoma .</brief_summary>
	<brief_title>Nab-paclitaxel Plus Gemcitabine Chinese Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Advanced pancreatic ductal adenocarcinoma fatal disease 6 month median overall survival ( OS ) . Gemcitabine approve single agent . Gemcitabine-based chemotherapy show benefit OS past decade . The recent phase III trial MPACT ( Metastatic Pancreatic Adenocarcinoma Clinical Trial ) demonstrate improvement overall response rate ( ORR ) , progression free survival ( PFS ) OS , nab-paclitaxel ( 125 mg/m2 day 1 , 8 15 every 28 day ) plus gemcitabine ( 1000 mg/m2 day 1 , 8 15 every 28 day ) compare gemcitabine alone . Accordingly combination nab-paclitaxel gemcitabine become one standard treatment metastatic pancreatic cancer . A Chinese phase II trial show modified dosage nab-paclitaxel ( 120 mg/m2 day 1 8 every 21 day ) plus gemcitabine ( 1000 mg/m2 day 1 8 every 21 day ) suitable Chinese patient . This study aim explore efficacy safety tentative dosage nab-paclitaxel ( 125 mg/m2 day 1 8 , every 21 day ) gemcitabine ( 1000 mg/m2 day 1 8 , every 21 day ) Chinese patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Signed informedconsent form . 2 . Age le 18 year . 3 . Histologically confirm locally advanced metastatic pancreatic ductal adenocarcinoma , RECIST measurable lesion . 4 . Eastern Cooperative Oncology Group ( ECOG ) 01 life expectation le 12 week . 5 . Patients must receive previous chemotherapy investigational therapy treatment metastatic disease . Prior treatment 5fluorouracil gemcitabine administer radiation sensitizer adjuvant setting allow , provide least 6 month elapse since completion last dose linger toxicity present . 6 . Adequate liver/bone marrow function . 7 . Human Chorionic Gonadotropin ( HCG ) test negative female contraception measure 3 month study end . 8 . Compliant , follow regularly . 1 . Pregnant breastfeed female , willing take contraception measure study . 2 . Serious infection require antibiotic intervention recruitment . 3 . Allergic study drug . 4 . More grade 1 neuropathy . 5 . Uncontrolled brain metastasis mental illness . 6 . Congestive heart failure , uncontrolled cardiac arrhythmia , etc . 7 . Other malignancy within 5 year . 8 . Ca n't follow obey protocol . 9 . Ineligible discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>nanoparticle albumin-bound paclitaxel</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>advanced pancreatic cancer</keyword>
</DOC>